LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 38 filers reported holding LYRA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,207,287 | +97.4% | 308,690 | +107.4% | 0.00% | – |
| Q2 2023 | $611,732 | +98.6% | 148,840 | 0.0% | 0.00% | – |
| Q1 2023 | $308,098 | +65873.9% | 148,840 | 0.0% | 0.00% | – |
| Q4 2022 | $467 | -99.9% | 148,840 | +1.3% | 0.00% | – |
| Q3 2022 | $735,000 | +8.1% | 146,859 | +21.9% | 0.00% | – |
| Q2 2022 | $680,000 | +353.3% | 120,476 | +221.6% | 0.00% | – |
| Q1 2022 | $150,000 | -4.5% | 37,464 | +4.0% | 0.00% | – |
| Q4 2021 | $157,000 | -52.3% | 36,018 | 0.0% | 0.00% | – |
| Q3 2021 | $329,000 | +13.8% | 36,018 | -0.2% | 0.00% | – |
| Q2 2021 | $289,000 | -72.4% | 36,102 | -60.0% | 0.00% | – |
| Q1 2021 | $1,046,000 | +33.9% | 90,281 | +31.8% | 0.00% | – |
| Q4 2020 | $781,000 | +72.8% | 68,517 | +69.1% | 0.00% | – |
| Q3 2020 | $452,000 | +20.5% | 40,510 | +22.2% | 0.00% | – |
| Q2 2020 | $375,000 | – | 33,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $5,580,568 | 1.20% |
| Perceptive Advisors | 9,146,730 | $28,720,732 | 0.81% |
| VR Adviser, LLC | 924,170 | $2,901,894 | 0.49% |
| Nantahala Capital Management | 2,220,830 | $6,973,406 | 0.45% |
| PURA VIDA INVESTMENTS, LLC | 2,157,298 | $6,773,916 | 0.35% |
| Soleus Capital Management, L.P. | 592,417 | $1,860,189 | 0.27% |
| Ikarian Capital, LLC | 343,685 | $1,079,171 | 0.26% |
| Clearline Capital LP | 119,128 | $374,062 | 0.07% |
| Anson Funds Management LP | 39,127 | $122,859 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $460,952 | 0.01% |